JP2015503610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503610A5 JP2015503610A5 JP2014551715A JP2014551715A JP2015503610A5 JP 2015503610 A5 JP2015503610 A5 JP 2015503610A5 JP 2014551715 A JP2014551715 A JP 2014551715A JP 2014551715 A JP2014551715 A JP 2014551715A JP 2015503610 A5 JP2015503610 A5 JP 2015503610A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- crystalline form
- compound
- following characteristic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586324P | 2012-01-13 | 2012-01-13 | |
| US61/586,324 | 2012-01-13 | ||
| PCT/IB2013/050283 WO2013105066A1 (en) | 2012-01-13 | 2013-01-11 | Salts of an ip receptor agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503610A JP2015503610A (ja) | 2015-02-02 |
| JP2015503610A5 true JP2015503610A5 (enExample) | 2016-02-25 |
| JP6058698B2 JP6058698B2 (ja) | 2017-01-11 |
Family
ID=47757663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551715A Expired - Fee Related JP6058698B2 (ja) | 2012-01-13 | 2013-01-11 | Ｉｐ受容体アゴニストの塩 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9174985B2 (enExample) |
| EP (1) | EP2802584B1 (enExample) |
| JP (1) | JP6058698B2 (enExample) |
| CN (1) | CN104169282B (enExample) |
| ES (1) | ES2561353T3 (enExample) |
| WO (1) | WO2013105066A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101491938B1 (ko) | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ｉｐ 수용체 효능제 헤테로시클릭 화합물 |
| US10744223B2 (en) | 2011-03-25 | 2020-08-18 | Szent Co. | Scented material compositions and articles for use with food and beverage |
| US9801969B2 (en) | 2011-03-25 | 2017-10-31 | Szent Bev Co. | Scented attachment for containers |
| US9174985B2 (en) | 2012-01-13 | 2015-11-03 | Novartis Ag | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists |
| UY34572A (es) | 2012-01-13 | 2013-09-02 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor ip |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| CN105189500A (zh) * | 2013-02-13 | 2015-12-23 | 诺华股份有限公司 | Ip受体激动剂杂环化合物 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| CN105801578B (zh) * | 2016-04-28 | 2018-06-22 | 华南理工大学 | 一种半饱和吡嗪衍生物的合成方法及应用 |
| USD826047S1 (en) | 2017-03-29 | 2018-08-21 | Szent Co. | Bottle ring |
| CN110877768B (zh) * | 2017-05-05 | 2022-05-06 | 圣特公司 | 一种用于制作香味传递系统的方法 |
| USD950384S1 (en) | 2018-05-16 | 2022-05-03 | Szent Co. | Bottle |
| US11097877B2 (en) | 2018-05-31 | 2021-08-24 | Szent Co. | Scent delivery and preservation systems and methods for beverage containers |
| WO2020099929A1 (en) | 2018-11-14 | 2020-05-22 | Roivant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
| US11018362B2 (en) | 2019-05-30 | 2021-05-25 | Lih-Ren Shiue | System for generating electricity using oxygen from water |
| US11312528B2 (en) | 2019-10-07 | 2022-04-26 | Szent Co. | Scented attachments for beverage cartons |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| EP0865302B1 (de) | 1995-12-07 | 2000-05-31 | Jago Pharma Ag | Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers |
| UA49878C2 (uk) | 1996-02-21 | 2002-10-15 | Шерінг Корпорейшн | Пристрій для інгаляції порошку (варіанти) |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| EP1632479B1 (en) | 1999-05-04 | 2011-01-12 | Schering Corporation | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives |
| IL145742A0 (en) | 1999-05-04 | 2002-07-25 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| TW200413372A (en) | 2002-09-18 | 2004-08-01 | Ono Pharmaceutical Co | Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| EP2300425A4 (en) * | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
| TWI368513B (en) * | 2009-04-30 | 2012-07-21 | Univ Kaohsiung Medical | Synthesis of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives, and rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction thereof |
| KR101491938B1 (ko) | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ｉｐ 수용체 효능제 헤테로시클릭 화합물 |
| US9174985B2 (en) | 2012-01-13 | 2015-11-03 | Novartis Ag | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists |
| WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| UY34572A (es) | 2012-01-13 | 2013-09-02 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor ip |
| CN105189500A (zh) | 2013-02-13 | 2015-12-23 | 诺华股份有限公司 | Ip受体激动剂杂环化合物 |
-
2013
- 2013-01-11 US US14/371,593 patent/US9174985B2/en not_active Expired - Fee Related
- 2013-01-11 CN CN201380013971.3A patent/CN104169282B/zh not_active Expired - Fee Related
- 2013-01-11 WO PCT/IB2013/050283 patent/WO2013105066A1/en not_active Ceased
- 2013-01-11 EP EP13707037.1A patent/EP2802584B1/en not_active Not-in-force
- 2013-01-11 JP JP2014551715A patent/JP6058698B2/ja not_active Expired - Fee Related
- 2013-01-11 ES ES13707037.9T patent/ES2561353T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503610A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2015520151A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2016517857A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| FI2744810T4 (fi) | Tenofoviirialafenamidihemifumaraatti | |
| JP2017528507A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2018509438A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JP2015500223A5 (enExample) | ||
| JP2017526724A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2020505354A5 (enExample) | ||
| JP2014509653A5 (enExample) | ||
| JP2016510768A5 (enExample) |